Etude visant à comprendre pourquoi certaines patientes atteintes d’un cancer de l’ovaire répondent mieux à l’immunothérapie

Objectif(s) de la recherche et intérêt pour la santé publique

Finalité de l'étude

Objectifs poursuivis

Domaines médicaux investigués

Bénéfices attendus

The aim of this substudy is to perform an analysis of non classical HLA pathways in ovarian cancer as predictive biomarker for immunotherapy and new immune target in ovarian cancer. We will performed panels with : HLA-E, HLA-G and ILT2 and analyse soluble HLA-G in plasma on the same to assess the predictive and prognostic value of non classical HLA in 475 patients from the ATALANTE clinical sutdy "A randomized, double blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab". Multivariate Cox models will be generated for progression-free (PFS) or overall (OS) survival. The Pearson correlation coefficient (r) was used to determine the linear correlation between HLA-E, HLA-G, ILT2 expressions and other immune markers (already test in ATALANTE trial).
Our data will be a strong rational to design future clinical trial with new immune checkpoint in ovarian cancer (NKG2A inhibitor or ILT2 inhibitor).